LAUSR

Objectives: Current cancer staging uses a 2-tier schema for stage I uterine leiomyosarcoma based on tumor size (≤5cm versus >5cm). Given the majority of stage I uterine leiomyosarcomas are >5cm in tumor size, this study examined the utility of a 3-tier schema (≤5cm, 5.1-10cm, and >10cm) in determining survival in stage I uterine leiomyosarcoma. Methods: This retrospective study queried the Surveillance, Epidemiology, and End Result 36 Program from 1988-2016. Surgically-treated stage I uterine leiomyosarcomas with known tumor size were examined (N=2,217). Trends, characteristics, and survival were assessed based on tumor size. Results: The most common tumor size was 5.1-10cm (45.7%) followed by >10cm (35.0%) and ≤5cm (19.4%). Tumor size-shift occurred during the study period and the number of tumor size >10cm increased from 12.9% to 44.5% whereas the number of other tumor size groups decreased (P 10cm versus ≤5cm reached nearly two-fold (hazard ratio 1.96, 95% confidence interval 1.78-2.16). Women with tumor size >10cm were nearly twice more likely to receive adjuvant chemotherapy versus those with Conclusions: In the past decades, tumors of stage I uterine leiomyosarcoma have become larger. A tumor size-based 3-tier staging system may be useful to differentiate survival in stage I uterine leiomyosarcoma. Tumor size appears to be a deciding factor for adjuvant chemotherapy use but it did not improve survival. Download : Download high-res image (108KB) Download : Download full-size image